0 (0%)		09-14 04:41
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	42.63	1-year :	45.33
Resists	First :	36.5	Second :	38.81
Pivot price	34.87
Supports	First :	32.77	Second :	27.27
MAs	MA(5) :	34.2	MA(20) :	34.97
	MA(100) :	27.99	MA(250) :	19.19
MACD	MACD :	-0.1	Signal :	0.2
%K %D	K(14,3) :	17.3	D(3) :	23.9
RSI	RSI(14): 49.2
52-week	High :	40.47	Low :	3.59

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LBPH ] has closed above bottom band by 35.9%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	34.85 - 35.04	35.04 - 35.22
Low:	32.69 - 32.94	32.94 - 33.17
Close:	33.95 - 34.32	34.32 - 34.66

Fri, 13 Sep 2024
When the Price of (LBPH) Talks, People Listen - Stock Traders Daily

Wed, 11 Sep 2024
Longboard Pharmaceuticals (NASDAQ:LBPH) Shares Gap Up to $34.51 - MarketBeat

Tue, 10 Sep 2024
Longboard Pharmaceuticals Boasts Valuable Epilepsy Drugs: Analyst - Longboard Pharmaceuticals (NASDAQ:LBPH) - Benzinga

Tue, 10 Sep 2024
Truist Financial Begins Coverage on Longboard Pharmaceuticals (NASDAQ:LBPH) - MarketBeat

Sun, 08 Sep 2024
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) - StockTitan

Wed, 28 Aug 2024
My Strategy For Longboard Pharma After Its Big Run (NASDAQ:LBPH) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	34 (M)
Shares Float	25 (M)
Held by Insiders	1.3 (%)
Held by Institutions	118.4 (%)
Shares Short	4,840 (K)
Shares Short P.Month	4,470 (K)

EPS	-2.17
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.57
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-24.1 %
Return on Equity (ttm)	-36.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.13
Qtrly Earnings Growth	0 %
Operating Cash Flow	-59 (M)
Levered Free Cash Flow	-34 (M)

PE Ratio	-15.89
PEG Ratio	0
Price to Book value	4.52
Price to Sales	0
Price to Cash Flow	-20.08

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.